<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Genes &amp; Cells</journal-id><journal-title-group><journal-title xml:lang="en">Genes &amp; Cells</journal-title><trans-title-group xml:lang="ru"><trans-title>Гены и Клетки</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Genes and Cells</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-1829</issn><issn publication-format="electronic">2500-2562</issn><publisher><publisher-name xml:lang="en">Human Stem Cells Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">120721</article-id><article-id pub-id-type="doi">10.23868/201805006</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Efficacy of combined use of plasmid constructs containing HGF and angiopoietin-1 genes to restore blood flow in ischemic tissues</article-title><trans-title-group xml:lang="ru"><trans-title>Эффективность сочетанного использования плазмидных конструкций, содержащих гены HGF и ангиопоэтина-1, для восстановления кровотока в ишемизированных тканях</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rubina</surname><given-names>KA. A</given-names></name><name xml:lang="ru"><surname>Рубина</surname><given-names>К. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Semina</surname><given-names>E. V</given-names></name><name xml:lang="ru"><surname>Семина</surname><given-names>Е. В</given-names></name></name-alternatives><email>e-semina@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Diykanov</surname><given-names>D. T</given-names></name><name xml:lang="ru"><surname>Дыйканов</surname><given-names>Д. Т</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Boldyreva</surname><given-names>M. A</given-names></name><name xml:lang="ru"><surname>Болдырева</surname><given-names>МА. A</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Makarevich</surname><given-names>P. I</given-names></name><name xml:lang="ru"><surname>Макаревич</surname><given-names>П. И</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Parfyonova</surname><given-names>Y. V</given-names></name><name xml:lang="ru"><surname>Акопян</surname><given-names>Ж. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Akopyan</surname><given-names>Zh. A</given-names></name><name xml:lang="ru"><surname>Парфенова</surname><given-names>Е. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tkachuk</surname><given-names>VA. A</given-names></name><name xml:lang="ru"><surname>Ткачук</surname><given-names>В. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">M.V. Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">Московский государственный университет им. М.В. Ломоносова</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Russian Cardiology Research and Production Complex</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр кардиологии</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Institute of Regenerative Medicine, Medical Research and Education Centre, M.V. Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">Институт регенеративной медицины медицинского научно-образовательного центра Московского государственного университета им. М.В. Ломоносова</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Russian Cardiology Research and Production Complex</institution></aff><aff><institution xml:lang="ru">Институт регенеративной медицины медицинского научно-образовательного центра Московского государственного университета им. М.В. Ломоносова</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Institute of Regenerative Medicine, Medical Research and Education Centre, M.V. Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр кардиологии</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-03-15" publication-format="electronic"><day>15</day><month>03</month><year>2018</year></pub-date><volume>13</volume><issue>1</issue><issue-title xml:lang="en">VOL 13, NO1 (2018)</issue-title><issue-title xml:lang="ru">ТОМ 13, №1 (2018)</issue-title><fpage>56</fpage><lpage>64</lpage><history><date date-type="received" iso-8601-date="2023-01-05"><day>05</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, Эко-Вектор</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://genescells.ru/2313-1829/article/view/120721">https://genescells.ru/2313-1829/article/view/120721</self-uri><abstract xml:lang="en"><p>New methods to stimulate blood supply of the ischemic organs and tissues are being intensively developed worldwide. These approaches are based on revascularization and remodeling of the newly formed blood vessels. This strategy was called therapeutic angiogenesis. Using in vitro, ex vivo and in vivo models we investigated the specific biological activity and angiogenic potential of Vascopoietin, which contained the plasmids for HGF and angiopoietin-1 expression. Vascopoietin stimulated vascular cell migration, proliferation and the formation of capillary-like structures in vitro and ex vivo. Using in vivo model of posterior limb ischemia in mice we demonstrated that Vascopoietin administration mediated stable HGF and angiopoietin-1 production resulting in new blood vessel formation and their stabilization in the ischemic muscles. In addition, Vascopoietin injection led to the restoration of the blood flow, decrease in the size of necrosis in ischemic limb and the reduction in the amputation frequency. The current data suggest Vascopoietin a promising drug for therapeutic angiogenesis.</p></abstract><trans-abstract xml:lang="ru"><p>В мире активно ведутся исследования, направленные на разработку методов и подходов для лечения ишемических заболеваний, в основе которых лежит стимуляция роста и ремоделирования кровеносных сосудов. Эта стратегия была названа терапевтическим ангиогенезом. Цель настоящей работы - на моделях in vitro, ex vivo и in vivo оценить специфическую биологическую активность и ангиогенный потенциал исследуемого вещества васкопоэтина, содержащего плазмиды для экспрессии HGF и ангиопоэтина-1. в модельных экспериментах in vitro и ex vivo было показано, что васкопоэтин оказывает стимулирующее действие на миграцию, пролиферацию и формирование капилляроподобных структур сосудистыми клетками. In vivo на модели ишемии задней конечности у мышей введение васкопоэтина обеспечивало стабильный синтез белков HGF и ангиопоэтина-1, что приводило к активации ангиогенеза и стабилизации вновь сформированных сосудов в ишемизированной мышце. Кроме того, при введении васкопоэтина было обнаружено восстановление кровотока в ишемизированной конечности, уменьшение размеров некроза и снижение частоты ампутаций. На основании полученных данных можно сделать вывод о наличии у васкопоэтина ангиогенной активности, что позволяет рассматривать его как перспективное средство для терапевтического ангиогенеза.</p></trans-abstract><kwd-group xml:lang="en"><kwd>hepatocyte growth factor</kwd><kwd>angiopoietin-1</kwd><kwd>Vascopoietin</kwd><kwd>gene therapy</kwd><kwd>angiogenesis</kwd><kwd>ischemia treatment</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>фактор роста гепатоцитов</kwd><kwd>ангиопоэтин-1</kwd><kwd>васкопоэтин</kwd><kwd>генная терапия</kwd><kwd>ангиогенез</kwd><kwd>лечение ишемии</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Deveza L., Choi J., Yang F. Therapeutic Angiogenesis for Treating Cardiovascular Diseases. Theranostics 2012; 2(8): 801-14.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Carmeliet P., Jain K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473(7347): 298-307.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Xu K., Cleaver O. Tubulogenesis during blood vessel formation. Semin. Cell Dev. Biol. 2011; 22(9): 993-1004.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Gupta R., Tongers J., Losordo D.W. Human Studies of Angiogenic Gene Therapy. Circ. Res. 2009; 105: 724-36.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis. Nat. Med. 2000; 6: 1102-13.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Morishita R., Aoki M., Hashiya N. et al. Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr. Gene Ther. 2004; 4: 199-206.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Shimamura M., Nakagami H., Taniyama Y. et al. Gene therapy for peripheral arterial disease. Expert Opin. Biol. Ther. 2014; 14(8): 1175-84.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Ono K., Matsumori A., Shioi T. et al. Enhanced expression of hepa-tocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 1997; 95(11): 2552-8.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Rincon M.Y., Vanden Driessche T. et al. Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovasc. Res. 2015; 108(1): 4-20.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Pospelova T.V., Bykova T.V., Zubova S.G. et al. Rapamycin induces pluripotent genes associated with avoidance of replicative senescence. Cell Cycle 2013; 12(24): 3841-51.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Semina E.V., Rubina K.A., Sysoeva V.Yu. et al. Three-Dimensional Model of Biomatrix as a Method of Studying Blood Vessels and Nerve Growth in Tissue Engineering Structures. Moscow University Chemistry Bulletin 2016; 71(3): 172-7.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Makarevich P., Tsokolaeva Z., Shevelev A. et al. Combined transfer of human VEGF165 and HGF genes renders potent angiogenic effect in ischemic skeletal muscle. PLoS One 2012; 7(6): e38776.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Макаревич П.И., Болдырева М.А., Дергилёв К.В. и соавт. Трансплантация клеточных пластов из мезенхимальных стромальных клеток жировой ткани эффективно индуцирует ангиогенез в ишемизированных скелетных мышцах. Г ены и Клетки 2015; 10(3): 68-77.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Shevchenko E., Makarevich P., Tsokolaeva Z. et al. Transplantation of modified human adipose derived stromal cells expressing VEGF165 results in more efficient angiogenic response in ischemic skeletal muscle. J. Transl. Med. 2013; 11: 138.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69: 4-10.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Min J.K., Lee Y.M., Kim J.H. et al. Hepatocyte Growth Factor Suppresses Vascular Endothelial Growth Factor-Induced Expression of Endothelial ICAM-1 and VCAM-1 by Inhibiting the Nuclear Factor-B Pathway. Circ. Res. 2005; 96: 300-7.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>De Haro J., Acin F., Lopez-Quintana A. et al. Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease. Heart Vessels 2009; 24: 321-8.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Deev R., Plaksa I., Bozo I. et al. Results of an International Postmarketing Surveillance Study of pl-VEGF165 Safety and Efficacy in 210 Patients with Peripheral Arterial Disease. Am. J. Cardiovasc. Drugs 2017; 17(3): 235-42.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kim J., Mirando A.C., Popel A.S. et al. Gene delivery nanoparticles to modulate angiogenesis. Adv. Drug Deliv. Rev. In press 2016.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Banfi G., von Degenfeld R., Gianni-Barrera S. et al. Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB. FASEB J. 2012; 26: 2486-97.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Makarevich P., Tsokolaeva Z., Shevelev A. et al. Combined transfer of human VEGF165 and HGF genes renders potent angiogenic effect in ischemic skeletal muscle. PLoS One 2012; 7(6): e38776.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Spanholtz T.A., Theodorou P., Holzbach T. et al. Vascular endothelial growth factor (VEGF165) plus basic fibroblast growth factor (bFGF) producing cells induce a mature and stable vascular network - a future therapy for ischemically challenged tissue. J. Surg. Res. 2011; 171: 329-38.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Kupatt C., Hinkel R., Pfosser A. et al. Cotransfection of vascular endothelial growth factor - A and platelet-derived growth factor-B via recombinant adeno-associated virus resolves chronic ischemic malperfusion role of vessel maturation. J. Am. Coll. Cardiol. 2010; 56: 414-22.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Su H., Takagawa J., Huang Y. et al. Additive effect of AAV-mediated angiopoietin-1 and VEGF expression on the therapy of infarcted heart. Int. J. Cardiol. 2009; 133: 191-7.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Yu J.X., Huang X.F., Lv W.M. et al. Combination of stromal-derived factor-1alpha and vascular endothelial growth factor genemodified endothelial progenitor cells is more effective for ischemic neovascularization. J. Vasc. Surg. 2009; 50: 608-16.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Макаревич П.И., Рубина К.А., Дыйканов Д.Т. и соавт. Терапевтический ангиогенез с применением факторов роста: современное состояние и перспективы развития. Кардиология 2015; 9: 59-71.</mixed-citation></ref></ref-list></back></article>
